PL2814829T3 - Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania - Google Patents

Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania

Info

Publication number
PL2814829T3
PL2814829T3 PL13704871T PL13704871T PL2814829T3 PL 2814829 T3 PL2814829 T3 PL 2814829T3 PL 13704871 T PL13704871 T PL 13704871T PL 13704871 T PL13704871 T PL 13704871T PL 2814829 T3 PL2814829 T3 PL 2814829T3
Authority
PL
Poland
Prior art keywords
conjugates
methods therefor
enediyne compounds
enediyne
compounds
Prior art date
Application number
PL13704871T
Other languages
English (en)
Inventor
Naidu S. Chowdari
Sanjeev Gangwar
Bilal Sufi
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47722570&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2814829(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL2814829T3 publication Critical patent/PL2814829T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13704871T 2012-02-13 2013-02-08 Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania PL2814829T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598143P 2012-02-13 2012-02-13
US201261653785P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
PL2814829T3 true PL2814829T3 (pl) 2017-06-30

Family

ID=47722570

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13704871T PL2814829T3 (pl) 2012-02-13 2013-02-08 Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania

Country Status (30)

Country Link
US (2) US8709431B2 (pl)
EP (1) EP2814829B1 (pl)
JP (1) JP6113194B2 (pl)
KR (1) KR101660146B1 (pl)
CN (1) CN104220441B (pl)
AR (1) AR089972A1 (pl)
AU (1) AU2013221873B2 (pl)
BR (1) BR112014019990A8 (pl)
CA (1) CA2864420C (pl)
CL (1) CL2014002096A1 (pl)
CO (1) CO7061078A2 (pl)
CY (1) CY1118899T1 (pl)
DK (1) DK2814829T3 (pl)
EA (1) EA027925B1 (pl)
ES (1) ES2615268T3 (pl)
HK (1) HK1204326A1 (pl)
HR (1) HRP20170334T1 (pl)
HU (1) HUE033704T2 (pl)
IL (1) IL233965B (pl)
LT (1) LT2814829T (pl)
MX (1) MX350539B (pl)
PE (1) PE20141791A1 (pl)
PL (1) PL2814829T3 (pl)
PT (1) PT2814829T (pl)
RS (1) RS55763B1 (pl)
SG (1) SG11201404667XA (pl)
SI (1) SI2814829T1 (pl)
TW (1) TW201336851A (pl)
WO (1) WO2013122823A1 (pl)
ZA (1) ZA201406723B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
MX368016B (es) * 2013-08-14 2019-09-13 Univ Rice William M Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.
EP3119803B1 (en) 2014-03-20 2019-09-11 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
PL3221363T3 (pl) 2014-11-21 2021-01-11 Bristol-Myers Squibb Company Przeciwciała przeciwko cd73 i ich zastosowanie
CN113929770A (zh) 2014-11-21 2022-01-14 百时美施贵宝公司 包含修饰的重链恒定区的抗体
EA037590B1 (ru) 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
CN107531720A (zh) * 2015-01-08 2018-01-02 斯克利普斯研究院 抗癌症候选药物
WO2016144608A1 (en) 2015-03-10 2016-09-15 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
SG11201805150QA (en) 2015-12-21 2018-07-30 Bristol Myers Squibb Co Variant antibodies for site-specific conjugation
BR112018067368A2 (pt) 2016-03-04 2019-01-15 Bristol-Myers Squibb Company terapia de combinação com anticorpos anti-cd73
CN106267188A (zh) * 2016-08-15 2017-01-04 深圳大学 小分子免疫激动剂偶联pd‑1抗体的新型抗体及其在抗肿瘤中的应用
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3720504A1 (en) * 2017-12-06 2020-10-14 Synaffix B.V. Enediyne conjugates
CN110183659B (zh) * 2018-02-21 2022-04-26 香港科技大学 含有杂环的聚合物、其制备方法及其应用
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR20210098488A (ko) 2018-11-30 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CA3140716A1 (en) * 2019-05-22 2020-11-26 Board Of Regents, The University Of Texas System Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
AU2022302784A1 (en) 2021-06-28 2023-12-21 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
US5162330A (en) * 1990-11-05 1992-11-10 Bristol-Myers Squibb Co. Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
CN1638800A (zh) 2002-01-09 2005-07-13 米德列斯公司 抗cd30的人类单克隆抗体
EP2261244A3 (en) 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
JP4680902B2 (ja) 2003-07-22 2011-05-11 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｒｇ１抗体及びその使用
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US8170637B2 (en) * 2008-05-06 2012-05-01 Neurosky, Inc. Dry electrode device and method of assembly
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EA200800094A1 (ru) 2005-06-20 2008-06-30 Медарекс, Инк. Антитела cd19 и их использование
WO2007038637A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
WO2007038868A2 (en) * 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
ATE534629T1 (de) 2005-10-26 2011-12-15 Medarex Inc Verfahren und verbindungen zur herstellung von cc-1065-analoga
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
SG170080A1 (en) 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
AU2006321841C1 (en) 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
KR100869414B1 (ko) 2005-12-13 2008-11-21 야마하 가부시키가이샤 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기
AU2007292891B2 (en) 2006-09-08 2012-04-12 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
KR20090122439A (ko) 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 단일 아미노산을 갖는 화학적 링커 및 이의 접합체
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof

Also Published As

Publication number Publication date
BR112014019990A2 (pl) 2017-06-20
CN104220441A (zh) 2014-12-17
IL233965B (en) 2018-01-31
HRP20170334T1 (hr) 2017-04-21
KR101660146B1 (ko) 2016-09-26
JP6113194B2 (ja) 2017-04-12
HK1204326A1 (en) 2015-11-13
EP2814829B1 (en) 2016-12-07
CO7061078A2 (es) 2014-09-19
AU2013221873A1 (en) 2014-10-02
HUE033704T2 (en) 2017-12-28
SG11201404667XA (en) 2014-09-26
PT2814829T (pt) 2017-02-15
US20130209494A1 (en) 2013-08-15
BR112014019990A8 (pt) 2017-07-11
TW201336851A (zh) 2013-09-16
DK2814829T3 (en) 2017-03-20
US20140193438A1 (en) 2014-07-10
CL2014002096A1 (es) 2014-11-28
AU2013221873B2 (en) 2016-11-17
ES2615268T3 (es) 2017-06-06
US8709431B2 (en) 2014-04-29
LT2814829T (lt) 2017-02-27
CN104220441B (zh) 2017-03-29
JP2015508074A (ja) 2015-03-16
CA2864420C (en) 2016-11-15
ZA201406723B (en) 2016-05-25
EP2814829A1 (en) 2014-12-24
CY1118899T1 (el) 2018-01-10
RS55763B1 (sr) 2017-07-31
EA027925B1 (ru) 2017-09-29
AR089972A1 (es) 2014-10-01
SI2814829T1 (sl) 2017-02-28
MX350539B (es) 2017-09-08
EA201491447A1 (ru) 2014-11-28
WO2013122823A1 (en) 2013-08-22
CA2864420A1 (en) 2013-08-22
US9156850B2 (en) 2015-10-13
MX2014009234A (es) 2014-11-10
KR20140120374A (ko) 2014-10-13
PE20141791A1 (es) 2014-11-19

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
HK1204326A1 (en) Enediyne compounds, conjugates thereof, and uses and methods therefor
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
GB201304967D0 (en) .
GB201204183D0 (en) .
EP2917244A4 (en) ANTIBODY CONJUGATES OBTAINED FROM APROTININE
HK1207317A1 (en) Substituted 1,6-naphthyridines 16-
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
ZA201409119B (en) Polymer-nsaid conjugate
EP2836238A4 (en) COPOLYMERKONJUGATE
GB201218713D0 (en) Improved padlock
GB201207426D0 (en) .
GB201206865D0 (en) .
GB201206866D0 (en) .
GB201205844D0 (en) .
GB201200117D0 (en) .